PRELIMINARY PROGRAMME EHMSG Workshop
Friday, September 12, 2025
08.30 – 08.45 hrs
Welcome Words | Congress Presidents and Authorities
European Helicobacter and Microbiota Study Group: a tale of friendship and science
Antonio Gasbarrini, Giovanni Gasbarrini
08.45 - 09.55 hrs | Session 01: Hot topics in gut microbiome and H. pylori
08.45 – 09.05 hrs
01.01 Gut microbiome for precision medicine
Eran Elinav, Rehovot, Israel
09.05 – 09.25 hrs
01.02 The Hardy strain of H. pylori: an ancient ecospecies
Kaisa Thorell, Gothenburg, Sweden
09.25 – 09.35 hrs
01.03. A novel multi-epitope-based vaccine against Helicobacter pylori: evaluation of protective and therapeutic efficacy
Behnam Kalali, Munich, Germany
09.35 – 09.45 hrs
01.04. TOGAS - Towards gastric cancer screening implementation in the European Union - WP 4 pilot study 1
Bojan Tepes, Ljubljana, Slovenia
09.45 – 09.55 hrs
01.05. The Impact of Encapsulated Fecal Microbiota Transplantation for Functional Dyspepsia: A Randomized, Placebo-Controlled, Double-Blind Study (FMT-FD Trial)
Ratha-korn Vilaichone, Pathumthani, Thailand
09.55 - 10.30 hrs | Coffee Break
10.30 - 11.40 hrs | Session 02: Oncobiome (Parallel Session)
10.30 – 10.50 hrs
02.01 Gut microbiome in colorectal cancer: from pathogenesis to clinical practice
Francis Chan, Hong Kong, China
10.50 – 11.10 hrs
02.02 Exploiting gut microbiome in oncology: opportunities and challenges
Gianluca Ianiro, Rome, Italy
11.10 – 11.20 hrs
02.03 Fecal microbiota transplantation in the management of immune checkpoint inhibitor-associated colitis and diarrhea: a case series
Franziska Deutschbein, Rome, Italy
11.20 – 11.30 hrs
02.04 Metatranscriptomics reveals distinct tumour microbiota in microsatellite stable and unstable colorectal Cancer
Patricia Vieira, Porto, Portugal
11.30 – 11.40 hrs
02.05 Impact of antibiotic exposure on survival outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta analysis
Margherita Ferrari, Rome, Italy
10.30 - 11.40 hrs |Session 03: Gastric Cancer Prevention (Parallel Session)
10.30 – 10.50 hrs
03.01 Primary Prevention
Jin Young Park, Lyon, France
10.50 – 11.10 hrs
03.02 Screening for H. pylori in combination to colorectal cancer screening
Yi-Chia Lee, Taipei, Taiwan
11.10 – 11.20 hrs
03.03. E-cadherin mutations activate a nucleus-dependent invasive program in gastric cancer
Joana Figueiredo, Porto, Portugal
11.20 – 11.30 hrs
03.04. IMvasion; targeting non-H. pylori bacterial invasion of the stomach during Intestinal Metaplasia for the prevention of gastric adenocarcinoma
Amanda Rossiter-Pearson, Birmingham, United Kingdom
11.30 – 11.40 hrs
03.05. The role of MUC13 in gastric cancer cell death inhibition.
Baptiste Oosterlinck, Antwerp, Belgium
11.40 - 12.40 hrs | Session 04: Industry-Sponsored Satellite Symposium 1
CLICK to view the detailed Programme
12.40 - 14.15 | Lunch Break & Poster Viewing
14.15 - 15.25 hrs | Session 05: Probiotics: a practical approach (Parallel Session)
14.15 – 14.35 hrs
05.01 40 Years Experience with Probiotics
Francisco Guarner, Barcelona, Spain
14.35 – 14.55 hrs
05.02 Probiotics in inflammatory bowel disease: myth or reality?
Franco Scaldaferri, Rome, Italy
14.55 – 15.05 hrs
05.03 Multistrain probiotics plus vitamin D improve gut barrier function and gut microbiota composition in irritable bowel syndrome without constipation: results from a double-blind, randomized, placebo-controlled trial
Lucrezia Laterza, Rome, Italy
15.05 – 15.15 hrs
05.04 Antimicrobial potential of commensal Neisseriae against Helicobacter pylori
Chiara Pagliuca, Naples, Italy
15.15 – 15.25 hrs
05.05 Comparative Effectiveness and Safety of Probiotics with Psychotropic Potential in Patients with Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis
Theodore Rokkas, Athens, Greece
14.15 – 15.25 hrs | Session 06: H. pylori management (Parallel Session)
14.15 – 14.35 hrs
06.01 From H2RAs to PPIs and P-CABs: the evolution of antisecretory drugs as a key component of H. pylori eradication regimens
Carmelo Scarpignato, Parma, Italy
14.35 – 14.55 hrs
06.02 Difficult to treat H. pylori patients
Rocco Maurizio Zagari, Bologna, Italy
14.55 – 15.05 hrs
06.03 Interim results of investigating possible negative effects of Helicobacter pylori test and treat on overall health in a GISTAR study participant cohort
Danute Razuka-Ebela, Riga, Latvia
15.05 – 15.15 hrs
06.04 Effectiveness of Helicobacter pylori eradication treatments in Primary Care: insights from a national real-world cohort
Olga Nyssen, Madrid, Spain
15.15 – 15.25 hrs
06.05 Hand-held, palm-size breathalyzer device and novel UBT for H. Pylori detection
Anastasia Rigas, Setauket, United States
15.25 – 16.00 hrs | Coffee Break
16.00 - 17.00 hrs | Session 07: Industry-Sponsored Satellite Symposium 2
CLICK to view the detailed Programme
17.00 - 18.10 hrs | Session 08: FMT (Parallel Session)
17.00 – 17.20 hrs
08.01 Challenges for biobanks
Christian Hvas, Aarhus, Denmark
17.20 – 17.40 hrs
08.02 From FMT to multimodal microbiome modulation
Jasmohan Bajaj, Richmond, VA, USA
17.40 – 17.50 hrs
08.03 Biovigilance in Faecal Microbiota Transplantation: a cohort study and framework for microbiological assessments of infectious adverse events
Vlada Chernova, Leiden, Netherlands
17.50 – 18.00 hrs
08.04 Informed therapeutic microbiome modulation for post-infectious irritable bowel syndrome: a pilot experience of a microbiome clinic
William Fusco, Rome, Italy
18.00 – 18.10 hrs
08.05 Fecal microbiota transplantation for severe and severe-complicated C. difficile infection: a 10-year experience from a referral centre
Andrea Severino, Rome, Italy
17.00 – 18.10 hrs | Session 09: HP and non-HP related Gastritis (Parallel Session)
17.00 – 17.20 hrs
09.01 Features of autoimmune gastritis in case of previous H.pylori Infection
Marco Vincenzo Lenti, Pavia
17.20 – 17.40 hrs
09.02 Autoimmune Gastritis in Korean Patients with Gastric Tumors: Clinicopathologic Correlations and Diagnostic Histological Features
Jun Haeng Lee, Seoul, Korea
17.40 – 17.50 hrs
09.03 S. anginosus induces gastric inflammation in germ free INS-GAS mice
Zeli Shen, Cambridge, United States
17.50 – 18.00 hrs
09.04 Non-Helicobacter pylori Helicobacter (NHPΗ) species in gastric biopsies from Greek symptomatic Patients
Beatriz Martinez-Gonzalez, Athens, Greece
18.00 – 18.10 hrs
09.05 A prospective multicenter surveillance of non-Helicobacter pylori Helicobacter infection in medical checkup individuals in Japan
Kengo Tokunaga, Tokyo, Japan
19.30 hrs | EHMSG Conference Dinner
Saturday, September 13, 2025
08.30 – 08.45 hrs | Session 10: Memorial Talk
08.30 – 08.45 hrs
10.01 In Memoriam Robin Warren
Barry Marshall, Sydney, Australia
(pre-recorded talk)
08.45 – 09.55 hrs | Session 11: Microbiota in chronic non-communicable disorders (Parallel Session)
08.45 – 09.05 hrs
11.01 The microbiome-dependent mechanisms that drive to noncommunicable disorders
Herbert Tilg, Innsbruck, Austria
09.05 – 09.25 hrs
11.02 Organoids: a tool to understand microbiome-gut interface in chronic noncommunicable disorders
Juozas Kupcinskas, Kaunas, Lithuania
09.25 – 09.35 hrs
11.03 107- Dynamic interactions between bacteria and fungi in the gut microbiota revealed through a community merging analysis approach
Konrad Lehr, Magdeburg, Germany
09.35 – 09.45 hrs
11.04 A proof-of-concept study on gut and saliva microbiota profiling in patients with metabolic syndrome, type 2 diabetes and obesity
Lorenza Putignani, Rome, Italy
09.45 – 09.55 hrs
11.05 Investigating the modulation of the microbiota-gut-brain axis in relation to glioblastoma
Océane Martin, Bordeaux, France
08.45 – 09.55 hrs | Session 12: H. pylori and microbiota: an evolutionary perspective (Parallel Session)
08.45 – 09.05 hrs
12.01 H. pylori where are we going?
Peter Malfertheiner, Munich, Germany
09.05 – 09.25 hrs
12.02 The gastric environment and microbiome with and without H. pylori infection
Annemieke Smet, Antwerp, Belgium
09.25 – 09.35 hrs
12.03. Long-Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea
Jae Myung Park, Seoul, Republic of Korea
09.35 – 09.45 hrs
12.04. Gastric microbiota profiling in patients with multidrug-resistant Helicobacter pylori infection
Alfizah Hanafiah, Kuala Lumpur, Malaysia
09.45 – 09.55 hrs
12.05. Recurrence/reinfection rates after H. pylori eradication treatment during childhood.
Sami Boukerrou, Brussels, Belgium
09.55 – 10.25 hrs | Coffee Break
10.25 – 11.35 hrs | Session 13: Microbiome: basic (Parallel Session)
10.25 – 10.45 hrs
13.01 Defining a healthy microbiome
Dirk Haller, Munich, Germany
10.45 – 11.05 hrs
13.02 The potential of gut microbiome analysis: from Earth ecology to medicine
Nicola Segata, Trento, Italy
11.05 - 11.15hrs
13.03. Composition of oral and gastric microbiota in autoimmune atrophic gastritis patients
Edith Lahner, Rome, Italy
11.15 – 11.25 hrs
13.04. Harnessing microbial-derived metabolites for gastric cancer stratification: a multi-omic machine learning approach
Rui Ferreira, Porto, Portugal
11.25 - 11.35 hrs
13.05. Gut microbiota monitoring in antibiotic-associated Clostridioides difficile infection
Christina Casén, Oslo, Norway
10.25 – 11.35 hrs | Session 14: H. pylori: basic (Parallel Session)
10.25 – 10.45 hrs
14.01 Gastric microbiota associated with gastric cancer and precancerous lesions in Helicobacter pylori-negative patients
Hyo-Joon Yang, Seoul, Korea
10.45 – 11.05 hrs
14.02 H. pylori resistance mechanisms
Sinead Smith, Dublin, Ireland
11.05 – 11.15 hrs
14.03 Genomic sequencing of multidrug-resistant Helicobacter pylori strains from patients of different Ethnicities
Alfizah Hanafiah, Kuala Lumpur, Malaysia
11.15 – 11.25 hrs
14.04. Hobit+ gastric tissue-resident memory T cells confer full protection from Helicobacter pylori re-Infection
Raquel Mejias-Luque, Munich, Germany
11.25 – 11.35 hrs
14.05. Emerging Resistance Pathways in Helicobacter pylori: A Genomic Study of Clinical Isolates in Ireland
Thomas Butler, Dublin, Ireland
11.35 - 12.35 hrs | Session 15: Industry-Sponsored Satellite Symposium 3
CLICK to view the detailed Programme
12.35 - 14.00 | Lunch Break & Poster Viewing
14.00 – 15.10 hrs | Session 16: Diet and microbiota: between good and evil (Parallel Session)
14.00 – 14.20 hrs
16.01 Early-life, diet, and gut microbiota
Omry Koren, Tel Aviv, Israel
14.20 – 14.40 hrs
16.02 The impact of ultra-processed foods on gut microbiome and gut barrier
Benoit Chassaing, Paris, France
14.40 – 14.50 hrs
16.03 A high-salt diet induces dynamic shifts in the composition of the gut microbiota in mice
Konrad Lehr, Magdeburg, Germany
14.50 – 15.00 hrs
16.04 From gut to brain: neuroinflammatory effects of OMVs from urease-producing bacteria
Celia Carlini, Porto Alegre, Brazil
15.00 – 15.10 hrs
16.05 Tiny particles, big impact: cholesterol nanoparticles for Helicobacter pylori eradication
Paula Parreira, Porto, Portugal
14.00 – 15.10 hrs | Session 17: H. pylori, microbiota, and the gut barrier (Parallel Session)
14.00 – 14.20 hrs
17.01 The multifaceted role of gut barrier in health and disease
Maria Rescigno, Pieve Emanuele, Italy
14.20 – 14.40 hrs
17.02 Truth and myths on the effect of acid suppressants on H.pylori and gut microbiota
Christian Schulz, Munich, Germany
14.40 – 14.50 hrs
17.03 CagA+ Helicobacter pylori infection increases colorectal cancer risk by disrupting intestinal homeostasis
Markus Gerhard, Munich, Germany
14.50 – 15.00 hrs
17.04 Sex differences & autophagy influences gastric microbiota diversity & composition
Isidora Simovic, Kensington, Australia
15.00 – 15.10 hrs
17.05 Long-term immunological changes determined by quadruple therapy regimens in patients with Helicobacter pylori infection in a South-European country
Elisa Gravito-Soares, Coimbra, Portugal
15.10 – 15.40 hrs Coffee Break
15.40 – 16.40 hrs | Session 18: Industry-Sponsored Satellite Symposium 4
CLICK to view the detailed Programme
16.40 – 17.25 | Session 19: Contribution of EHMSG and TOGAS towards the burden of H.pylori globally
16.40 – 16.50 hrs
19.01. Tips and tricks for developing a successful international registry on H. Pylori
Olga Nyssen, Madrid, Spain
16.50 – 17.00 hrs
19.02. Gastric cancer prevention strategies in Latin America: The HOPE project
Arnoldo Riquelme, Santiago, Chile
17.00 – 17.10 hrs
19.03. African perspective
Mashiko Setshedi, Cape Town, South Africa
17.10 – 17.20 hrs
19.04. Asian perspective
Yoshio Yamaoka, Yufu, Japan
17.25 – 18.30 hrs | Session 20: Closing Session
17.25 – 17.35 hrs
20.01 Awarding of the Marshall and Warren Medal 2025 to Prof. Carmelo Scarpignato
17.35 – 17.50 hrs
20.02 Awarding of the EHMSG Oral and Poster Awards
17.50 – 18.00 hrs
20.03 Recognition of supporters
18.00 – 18.10 hrs
20.04 Presentation of the EHMSG Journal by Francesco Franceschi, Italy
18.10 – 18.25 hrs
20.05 Presentation of the next meeting in Belgrade by Mirjana Rajilic-Stojanovic, Serbia
18.25 – 18.30 hrs
Closing Remarks by Gianluca Ianiro